Bivalent COVID-19 vaccine effectiveness assessed in immunocompetent adults across nine states

An observational study was conducted using data from the VISION Network across nine states. The population consisted of immunocompetent adults aged 18 years or older. The study aimed to evaluate the effectiveness of updated (bivalent) COVID-19 vaccines in preventing COVID-19-associated emergency department and urgent care visits and hospitalizations. A specific comparator group was not reported.

The main results for the primary outcome of preventing COVID-19-associated emergency department, urgent care, and hospital visits were not reported. No effect size, absolute numbers, p-values, or confidence intervals were provided. The direction of the effect was also not reported. No secondary outcomes were listed.

No safety or tolerability data were reported, including information on adverse events, serious adverse events, or discontinuations. The study's follow-up duration was not specified. Key limitations were not detailed in the provided information, and funding sources or potential conflicts of interest were not reported. The practice relevance of these findings cannot be determined without the complete results and methodological details from the full study.